Skip to main content

Year: 2020

IEC Announces Fiscal 2020 Fourth Quarter and Year End Results

REVENUE OF $46.4 MILLION IN THE QUARTER; UP 5.7% YEAR OVER YEARGROSS MARGIN OF 14.5% IN THE QUARTERGENERATED $7.3 MILLION OF OPERATING CASH FLOW IN THE QUARTERNEWARK, N.Y., Nov. 20, 2020 (GLOBE NEWSWIRE) — IEC Electronics Corp. (Nasdaq: IEC) today announced results for the fiscal 2020 fourth quarter and year ended September 30, 2020 (“fiscal 2020”).IEC reported revenues of $46.4 million for the fourth quarter of fiscal 2020, an increase of 5.7% as compared to revenues of $43.9 million for the fourth quarter of the year ended September 30, 2019 (“fiscal 2019”). Gross profit for the fourth quarter of fiscal 2020 was $6.7 million, or 14.5% of sales, compared to gross profit of $6.4 million, or 14.6% of sales in the fourth quarter of fiscal 2019. Selling and administrative expenses were $3.8 million in the fourth quarter of fiscal 2020,...

Continue reading

Gulf & Pacific Equities Corp. reports on Third Quarter Results with Revenue of $899,642

TORONTO, Nov. 20, 2020 (GLOBE NEWSWIRE) — Gulf & Pacific Equities Corp. (TSX-V: GUF) an established company focused on the acquisition, management and development of anchored shopping centres in Western Canada, reports a 18.5% decrease in revenues to $899,642 in the third quarter of 2020 from $1,103,183 at same period last year.Details of the nine and three months financial results for fiscal 2020 and 2019 under International Financial Reporting Standards (IFRS) as summarized below are also available at www.sedar.com or at the company’s website www.gpequities.com.About Gulf & Pacific Equities Corp.Gulf & Pacific Equities Corp. was incorporated under the laws of the Province of Alberta on April 8, 1998 and thereafter completed a public offering of common shares by prospectus dated June 26, 1998 (TSX-V: GUF). The Company acquires,...

Continue reading

Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of Directors

Prof. June is a world authority on immune tolerance and adoptive immunotherapyAppointment reaffirms AC Immune’s scientific leadership in neurodegenerationLAUSANNE, Switzerland, Nov. 20, 2020 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Prof. Carl H. June, a world authority on mechanisms related to immune tolerance and adoptive immunotherapy in the fields of chronic inflammation and cancer, was elected to the Company’s Board of Directors, at an extraordinary shareholders’ meeting today.Prof. June is a true pioneer in the field of immunotherapy most well-known for his research into T cell therapies for the treatment of cancer, who, in 2020, was elected to the American Philosophical Society. His...

Continue reading

CSOL Holding Ltd. reports third quarter 2020 financial results

CSOL Holding’s EBITDA for the first nine months of 2020 amounted to USD 55.5 million and the corresponding EBITDA margin was 27.3%. Sales amounted to USD 203.5 million, up 1.8% compared to the first nine months of 2019, mainly due to increases in mangoes, grapes, tangerines and avocados volumes. LTM Sales and EBITDA amounted to USD 330.2 million and USD 123.3 million respectively. As of September 30th, 2020, the Company maintained a cash balance of USD 33.9 million and a net leverage ratio of 3.4x.The Company continues executing its strategy to become a year-round supplier of fresh fruit to our global clients complementing its Peruvian window operations with investments in Colombia, Uruguay and lately in Chile, and capitalizing on its commercial and logistic platforms.“Despite the global pandemic context, the Company has achieved...

Continue reading

Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021

Promising Progress on Clinical Development Progress, Collaborations and PartneringMutually Ended Discussion on Medical Cannabis Commercial and Merger AgreementsTEL AVIV, Israel, Nov. 20, 2020 (GLOBE NEWSWIRE) — Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the third quarter ended September 30, 2020. Subsequent to the end of the third quarter, the Company announced several other key achievements subsequent to the end of the third quarter that position it for continued success in 2021, including clinical and operational objectives:Initiated its clinical trial in the U.S. The trial is being performed at Washington University School of Medicine in St. Louis, Missouri, which is among the leading medical...

Continue reading

AGF annonce les distributions annuelles estimées réinvesties de gains en capital pour les FNB AGF

TORONTO, 20 nov. 2020 (GLOBE NEWSWIRE) — Placements AGF Inc. (AGF) a annoncé aujourd’hui les distributions annuelles estimées réinvesties de 2020, pour les FNB AGF inscrits à la Bourse de Toronto ou à la NEO Bourse. Ces distributions annuelles estimées réinvesties représentent généralement les gains en capital réalisés dans le cadre des FNB AGF. Elles ne seront pas versées en espèces, mais plutôt réinvesties et déclarées à titre de gains imposables.Les distributions annuelles réinvesties seront versées en tant que distributions théoriques. De telles distributions sont produites quand les parts associées aux distributions réinvesties sont immédiatement consolidées avec les parts qui étaient détenues avant la distribution. Le nombre de parts détenues après la distribution est ainsi identique au nombre de parts détenues auparavant....

Continue reading

AGF Announces Estimated Annual Reinvested Capital Gains Distributions for AGF ETFs

TORONTO, Nov. 20, 2020 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF) today announced the estimated annual 2020 reinvested distributions for the AGF ETFs listed on the Toronto Stock Exchange or NEO Exchange. These estimated annual reinvested distributions generally represent realized capital gains within the AGF ETFs and will not be paid in cash, but will be reinvested and reported as taxable.The annual reinvested distributions will be paid in the form of a notional distribution. A notional distribution is when the units from a reinvested distribution are immediately consolidated with the units held prior to the distribution. The number of units held after the distribution is therefore identical to the number of units held before the distribution. The unitholder’s adjusted cost base for the respective AGF ETF may increase.Further...

Continue reading

Jushi Holdings Inc. Increases Equity Ownership Interest in Dalitso LLC, the Company’s Majority-Owned, Virginia-Based Pharmaceutical Processor Permit Holder

Jushi Holdings Inc. Increased Equity Ownership Interest in Dalitso LLC to 79%BOCA RATON, Fla., Nov. 20, 2020 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCMKTS: JUSHF), a vertically integrated, multi-state cannabis operator, announced it has purchased an additional 17.235% of the issued and outstanding equity of Dalitso LLC (Dalitso), a Virginia-based pharmaceutical processor. The Company now owns 79% of the issued and outstanding equity of Dalitso.Dalitso is one of only five applicants to have received conditional approval for a pharmaceutical processor permit issued by the Virginia Board of Pharmacy, and one of only four to have received final approval and permit issuance in the Commonwealth. Dalitso’s permit allows the Dalitso to cultivate, process, dispense and deliver medical cannabis to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.